問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳苓諭
下載
2020-03-01 - 2025-03-31
Condition/Disease
-
Test Drug
Participate Sites3Sites
Recruiting3Sites
2020-04-01 - 2025-11-26
Participate Sites7Sites
Not yet recruiting2Sites
Recruiting4Sites
Terminated1Sites
2018-12-01 - 2019-11-07
Carcinoma, Squamous Cell of Head and Neck Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma
Durvalumab (MEDI4736) Tremelimumab
Participate Sites5Sites
Not yet recruiting1Sites
2022-02-01 - 2029-12-31
Participate Sites9Sites
Recruiting9Sites
2020-03-01 - 2027-12-31
全部
